Efficacy and Tolerability of Moclobemide in Comparison with Placebo, Tricyclic Antidepressants, and Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients: A Clinical Overview

@article{Amrein1997EfficacyAT,
  title={Efficacy and Tolerability of Moclobemide in Comparison with Placebo, Tricyclic Antidepressants, and Selective Serotonin Reuptake Inhibitors in Elderly Depressed Patients: A Clinical Overview},
  author={R. Amrein and Max Stabl and Stephan A. Henauer and Erhard Affolter and I. Jonkanski},
  journal={The Canadian Journal of Psychiatry},
  year={1997},
  volume={42},
  pages={1043 - 1050}
}
Objective: To review the efficacy and safety of moclobemide in comparison with TCAs(for our purposes, “TCAs” will represent tricyclic and tetracyclic antidepressants, including maprotilin and mianserin) and selective serotonin reuptake inhibitors (SSRIs) in elderly depressed patients. Methods: The efficacy data reviewed were obtained from the following sources: 1) results of published studies in the elderly; 2) data on patients aged ≥ 60 years extracted from all available controlled trials in… Expand
Moclobemide: therapeutic use and clinical studies.
  • U. Bonnet
  • Psychology, Medicine
  • CNS drug reviews
  • 2003
Moclobemide is a reversible inhibitor of monoamine-oxidase-A (RIMA) and has been extensively evaluated in the treatment of a wide spectrum of depressive disorders and less extensively studied inExpand
Clinical pharmacology of moclobemide during chronic administration of high doses to healthy subjects
TLDR
The maximum tolerated dose of moclobemide in healthy subjects is 600”mg b.i.d. provided the tyramine content in a meal is not higher than 50 mg, and the incidence and intensity of adverse events was dose-dependent. Expand
Effects of Moclobemide on Event-related Potentials of Depressed Patients — a Preliminary Study
Abstract Objective: Moclobemide is a reversible inhibitor of monoamine oxidase-A and has become well established as an antidepressant, primarily because of its non-sedating effect and safety. ThisExpand
Antidepressants, old and new. A review of their adverse effects and toxicity in overdose.
  • J. Sarko
  • Medicine
  • Emergency medicine clinics of North America
  • 2000
The newer antidepressants are as efficacious as the older agents in the treatment of depression. They have a side effect profile that is different from the older drugs and are generally betterExpand
General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry
TLDR
The spectrum of different antidepressant treatments has broadened over the last few decades and the efficacy and clinical effectiveness of antidepressants is statistically significant, clinically relevant, and proven repeatedly. Expand
Drug and ECT treatment of depression in the elderly, 1996–2001: a literature review
TLDR
These recent publications support the conclusions from prior reviews that antidepressants and ECT are effective and safe treatments for depressed elderly patients. Expand
Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset
TLDR
Reversible MAO-A inhibition with moclobemide appears as an effective way to increase the anti-parkinsonian action of L-DOPA, without negatively affecting dyskinesia or dopaminergic psychosis. Expand
Tratamento de idosos com depressão utilizando tricíclicos, IMAO, ISRS e outros antidepressivos
TLDR
Data on the efficacy and safety of antidepressant agents currently available for the treatment of the elderly are reviewed, and information is included about thetreatment of specific populations such as physically frail patients and dementia adults. Expand
Quality assessment of meta-analyses of RCTs of pharmacotherapy in major depressive disorder
TLDR
A need exists for adherence to standardized reporting and quality guidelines in MAs of RCTs of pharmacotherapy for major depressive disorder in adults without co-morbidities and examine trends over time. Expand
Clinical considerations of antidepressant prescribing for older patients.
TLDR
This paper provides a review of current literature and makes recommendations for the pharmacological management of depression in older patients within the New Zealand context. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 39 REFERENCES
Selective serotonin reuptake inhibitors (SSRIs) in the treatment of elderly depressed patients: a qualitative analysis of the literature on their efficacy and side‐effects
TLDR
The results indicated that at the end of the treatment periods (4–8 weeks) all antidepressants were equally effective, and different side-effect profiles were found. Expand
Moclobemide. An update of its pharmacological properties and therapeutic use.
Unlike older monoamine oxidase inhibitors, which irreversibly and nonselectively bind monoamine oxidase (MAO), moclobemide is a reversible and selective inhibitor of the MAO-A isozyme. MoclobemideExpand
Moclobemide : A Review of its Pharmacological Properties and Therapeutic Use in Depressive Illness.
TLDR
With its efficacy against endogenous and nonendogenous depression, relatively rapid onset of antidepressant activity, and absence of carry-over effects on treatment withdrawal, moclobemide is likely to make an important contribution to the treatment of major depressive illness. Expand
Efficacy and tolerability of moclobemide compared with imipramine in depressive disorder (DSM-III): an Austrian double-blind, multicentre study.
The antidepressant efficacy, tolerability, and safety of moclobemide, a reversible, monoamine oxidase-A inhibitor, were compared with those of imipramine in parallel groups of patients with a majorExpand
A double-blind comparative trial of moclobemide v. imipramine and placebo in major depressive episodes.
TLDR
Patients suffering from a major depressive episode according to DSM-III criteria were randomly allocated to groups receiving either moclobemide, imipramine, or placebo treatment, and the overall assessment of tolerance clearly favoured placebo and moclOBemide over imipramsine. Expand
Clinical Activity and Tolerability of Trazodone, Mianserin, and Amitriptyline in Elderly Subjects with Major Depression: A Controlled Multicenter Trial
TLDR
A comparable therapeutic response but a better tolerance for atypical antidepressants, particularly TRA, make advisable the use of the latter drug in the elderly population, and GDS seems to be most reliable in detecting changes in elderly depressive symptomatology. Expand
A Retrospective Chart Review of Antidepressant Use, Effectiveness, and Adverse Effects in Adults Age 70 and Older.
  • Mamatha Kamath, S. Finkel, M. Moran
  • Medicine
  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 1996
TLDR
Many older patients who undergo antidepressant therapy discontinue because of side effects; however patients are likely to improve or recover with sustained therapy. Expand
Effects of Moclobemide on Depressive Symptoms and Cognitive Performance in a Geriatric Population: A Controlled Comparative Study Versus Imipramine
TLDR
Results indicate that moclobemide could prove to be the drug of choice in geriatric depression, given that cognitive effects are prominent in the aged. Expand
Reversible and selective inhibitors of monoamine oxidase A in the treatment of depressed elderly patients
TLDR
Clinical studies show that, in elderly depressed patients, moclobemide is at least as effective as other antidepressants, and is as well tolerated in elderly people as in younger people. Expand
Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly
TLDR
The results indicated a response rate of approximately 60% for both nortriptyline and phenelzine versus a 13% response rate for placebo, and both drugs were well tolerated. Expand
...
1
2
3
4
...